Cargando…

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients

BACKGROUND: Optimizing HCV genotype 1 therapy in terms of response prediction and tailoring treatment is undoubtedly the cornerstone of treating HIV co-infected patients in clinical practice. Accordingly, our aim was to analyze the predictive value of HCV viral decline for sustained virological resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivero-Juarez, Antonio, López-Cortés, Luis F., Camacho, Angela, Torres-Cornejo, Almudena, Gordon, Ana, Ruiz-Valderas, Rosa, Torre-Cisneros, Julian, Pineda, Juan A., Viciana, Pompeyo, Rivero, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063713/ https://www.ncbi.nlm.nih.gov/pubmed/24945348 http://dx.doi.org/10.1371/journal.pone.0099468

Ejemplares similares

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
por: Rizk, Hanan H., et al.
Publicado: (2016)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
por: Menard, Amélie, et al.
Publicado: (2012)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2015)

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients
por: López-Cortés, Luis F., et al.
Publicado: (2012)

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients
por: Rivero-Juarez, Antonio, et al.
Publicado: (2013)

Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2014)

Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV
por: Rivero-Juárez, Antonio, et al.
Publicado: (2013)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study
por: Lin, Chih Ying, et al.
Publicado: (2020)

Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients
por: Corchado, Sara, et al.
Publicado: (2014)

Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
por: Baumgarten, A, et al.
Publicado: (2010)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
por: Merchante, Nicolás, et al.
Publicado: (2015)

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
por: Flynn, Jacqueline K, et al.
Publicado: (2014)

European vs. Egyptian HCV-4 Patients with Elevated Baseline HCV RNA, Treated with PEG-IFN-α2a and Ribavirin: The Role of Rapid and Early Virologic Response
por: Dimitroulopoulos, Dimitrios, et al.
Publicado: (2010)

Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines
por: Torres-Cornejo, Almudena, et al.
Publicado: (2017)

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
por: Laouénan, C, et al.
Publicado: (2015)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals
por: Rivero-Juárez, Antonio, et al.
Publicado: (2020)

CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV
por: Lin, Chia-Chen, et al.
Publicado: (2017)

Correlates of HCV seropositivity among familial contacts of HCV positive patients
por: La Torre, Giuseppe, et al.
Publicado: (2006)

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population
por: Jin, Young-Joo, et al.
Publicado: (2013)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
por: BenMarzouk-Hidalgo, Omar J., et al.
Publicado: (2015)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection
por: Real, Luis Miguel, et al.
Publicado: (2019)

What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis
por: Skaathun, Britt, et al.
Publicado: (2020)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

1(OH) Vitamin D3 Supplementation Improves the Sensitivity of the Immune-Response during Peg-IFN/RBV Therapy in Chronic Hepatitis C Patients-Case Controlled Trial
por: Kondo, Yasuteru, et al.
Publicado: (2013)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
por: Brochado, Óscar, et al.
Publicado: (2021)

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study
por: López-Cortés, Luis F, et al.
Publicado: (2010)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients
por: Bokharaei-Salim, Farah, et al.
Publicado: (2016)

Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV
por: Jahan, Shah, et al.
Publicado: (2011)

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis
por: Medvedev, Regina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9nuatm2rp3u4o5mjo4nfn6k65n